AstraZeneca Ultomiris trial fails to meet primary endpoints for post-transplant indication

AstraZeneca's Phase 3 trial for Ultomiris in a post-transplant indication failed to demonstrate clinical efficacy. The failure represents a setback for the company's pipeline expansion efforts for its top-selling drug, though the impact on overall revenue remains limited by the drug's existing market approvals.